# 2026-08588: DEA Greenlights Bulk Psychedelic Production for Medical Trials

2026-08588, Bulk Manufacturer of Controlled Substances Application: Patheon API Inc., is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2026-05-04, effective Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before July 6, 2026. Such persons may also file a written request for a hearing on the application on or before July 6, 2026.; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-08588
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08588
- Title: Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 24008
- Published: 2026-05-04
- Effective: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before July 6, 2026. Such persons may also file a written request for a hearing on the application on or before July 6, 2026.
- Comments close: 2026-07-06
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

DEA Greenlights Bulk Psychedelic Production for Medical Trials

## Summary

Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.

## Abstract

Patheon API Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

## Effects PRIA read

- Application to Bulk-Manufacture Schedule I Psychedelics: benefit, low. Patheon API Inc. applied on February 9, 2026 to be registered to bulk manufacture three Schedule I controlled substances: dimethyltryptamine (drug code 7435), psilocybin (drug code 7437), and psilocyn (drug code 7438). The company says the planned manufacturing is for research and clinical trials o…
- Comment and Hearing Deadline for Stakeholders: benefit, low. Registered bulk manufacturers of the affected substances and applicants may submit electronic comments or objections, or file a written request for a hearing, on or before July 6, 2026 via the Federal eRulemaking Portal (https://www.regulations.gov). The notice provides a Comment Tracking Number up…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-08588 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/04/2026-08588/bulk-manufacturer-of-controlled-substances-application-patheon-api-inc)
- [2026-08588 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-04/pdf/2026-08588.pdf)

## Related
- [Previous: 2026-08587, Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.](https://policyrisk.com/federal-register/2026-08587)
- [Next: 2026-08589, Notice of Intent To Grant a Partially Exclusive Patent License](https://policyrisk.com/federal-register/2026-08589)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08588 (as of 2026-06-08).
